Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/202412279

Multidisciplinary Approaches to Breast Cancer: An Updated Review for Healthcare Providers.

Noor Naif Alaswad Alazmi [(1)] , Saleh Mubarak S. Aldawsari [(2)] , Reyouf Mazen Alhunaishel [(3)] , Rimah shaker Abdullah alkhonizi [(4)] , Rasha Shaker Alkhonizi , Mohammed Saad Abdullah Binseaidan [(5)] , Sharifah Gamea Almutairy [(6)] , Asaad Ali Mohammed Habbash [(7)] , Abdullah Abdullah Saleh altamimi [(8)]

(1) Aljouf cluster - Algharib PHC, Ministry of Health, Saudi Arabia,
(2) First Badr Primary health care Center, Riyadh First Health Cluster, Riyadh,Ministry of Health, Saudi Arabia,
(3) Mansoura Health Center – Riyadh,Ministry of Health, Saudi Arabia,
(4) Ministry of health, Saudi Arabia,
(5) Prince Salman Bin Mohammed Hospital in Dallam, Ministry of Health, Saudi Arabia,
(6) Public Health, Ministry of Health, Saudi Arabia,
(7) Tabuk Health Cluster, ERADH Complex For Mental Health, Tabuk, Ministry of Health, Saudi Arabia,
(8) Hotat bni tamim hospital,Ministry of Health, Saudi Arabia

Abstract

Background: Breast cancer persists as the most common cancer and a leading cause of cancer-related mortality in women worldwide. Its development is multifactorial, involving genetic, hormonal, and environmental risk factors. Significant global disparities in incidence and mortality exist, influenced by access to screening and advanced treatments.

Aim: This article provides a comprehensive, updated review of multidisciplinary approaches to breast cancer for healthcare providers. It aims to synthesize current evidence on etiology, diagnosis, staging, and the integrated management strategies that define modern oncology care.

Methods: The review synthesizes established clinical guidelines and current evidence across specialties. It details the diagnostic "triple assessment" (clinical exam, imaging, biopsy), the critical role of molecular subtyping (Luminal A/B, HER2-enriched, Basal-like), and the TNM staging system. Management strategies are explored through the lens of a multidisciplinary team, encompassing surgical, radiation, and medical oncology.

Results: Treatment is highly individualized based on stage and biology. Early-stage disease is managed with curative intent using breast-conserving surgery or mastectomy, often combined with adjuvant radiotherapy, chemotherapy, endocrine, or targeted therapy. Neoadjuvant chemotherapy is increasingly used for locally advanced and aggressive subtypes to downstage tumors. For metastatic disease, treatment focuses on prolonging survival and quality of life with systemic therapy. The integration of targeted agents (e.g., anti-HER2, CDK4/6 inhibitors) and immunotherapy has significantly improved outcomes.

Conclusion: A multidisciplinary, personalized approach is paramount for optimizing breast cancer care, improving survival, and managing treatment-related complications.

Keywords: Breast Cancer, Multidisciplinary Care, Molecular Subtypes, Targeted Therapy, TNM Staging, Personalized Medicine.

Introduction

Breast cancer is the most common cancer diagnosed in women and the second most common cause of death from cancer among women worldwide, representing a major global public health challenge and a leading contributor to morbidity and mortality across diverse populations [1]. The female breast is a paired glandular organ of variable size and density that lies superficial to the pectoralis major muscle and is composed of lobules, ducts, adipose tissue, fibrous stroma, blood vessels, and lymphatics, all of which can participate in benign and malignant processes [2]. Milk-producing cells are arranged in lobules, which are grouped into larger lobes separated by fat, while acini within these lobules produce milk and other secretions that are transported through a branching system of lactiferous ducts converging toward and exiting at the nipple [2]. The entire glandular structure is supported and anchored to the underlying muscular fascia by fibrous septa known as Cooper ligaments, which help maintain breast shape and position but may become distorted in malignancy, leading to clinical signs such as skin dimpling or retraction [2]. Breast cancer most commonly arises from the epithelial lining of the ducts, giving rise to ductal carcinoma, although a substantial number of cases originate in the

*Corresponding author e-mail: Nornaif111@gmail.com (Noor Naif Alaswad Alazmi).
Receive Date: 1 December 2024, Revise Date: 30 December 2024, Accept Date: 31 December 2024

lobules, resulting in lobular carcinoma; both in situ and invasive forms are recognized, with differing patterns of spread, prognostic implications, and responses to therapy [1]. Multiple risk factors for breast cancer have been well described, including increasing age, family history, genetic mutations such as BRCA1 and BRCA2, reproductive and hormonal factors, prior chest irradiation, lifestyle factors including obesity and alcohol use, and certain benign breast diseases, all of which contribute to an individual's cumulative lifetime risk [1],[3]. In many Western countries, population-based screening programs—particularly mammographic screening—have successfully shifted the pattern of detection so that a majority of breast cancers are identified at earlier stages through screening rather than through symptomatic presentation, contributing to improved survival outcomes [3]. By contrast, in many low- and middle-income settings, limited access to screening, diagnostic services, and awareness means that a palpable breast mass, skin changes, or abnormal nipple discharge often remains the primary mode of presentation, frequently at more advanced stages of disease [3].

Diagnosis of breast cancer typically relies on a triple assessment approach that integrates careful clinical breast examination, appropriate breast imaging such as mammography, ultrasound, or magnetic resonance imaging, and histopathologic confirmation via tissue biopsy, often using core needle techniques to allow for receptor and molecular profiling [1]. Once the diagnosis is established, contemporary management is multimodal and individualized, incorporating combinations of surgery, chemotherapy, radiation therapy, endocrine (hormonal) therapy, targeted biological agents, and more recently, immunotherapy, selected according to tumor biology and patient factors [1]. Key determinants of treatment strategy include histologic subtype, tumor grade and stage, lymph node status, expression of hormone receptors and HER2, proliferative indices, and the presence of germline or somatic genetic abnormalities, all of which enable risk stratification and personalization of care [1]. Through ongoing advances in screening, early detection, systemic therapies, and supportive care, outcomes for many patients with breast cancer have improved substantially, yet global disparities in access to these interventions remain a critical challenge for clinicians, health systems, and policymakers [1],[3].

Etiology: Breast Cancer Risk Factors

Identifying and understanding the factors associated with an increased incidence of breast cancer is fundamental to guiding effective screening strategies, early detection efforts, and individualized risk assessment for women across different age groups and clinical backgrounds. Breast cancer is a multifactorial disease in which genetic, hormonal, environmental, and lifestyle components interact in complex ways to influence the likelihood of disease development. These risk determinants vary considerably in magnitude, and while some are modifiable, many others are intrinsic or related to a woman's biological and reproductive profile. Comprehensive evaluation of these factors allows clinicians to tailor surveillance, counsel patients appropriately, and identify women who may benefit from genetic testing, enhanced screening modalities, or risk-reduction measures [4]. Age remains one of the most significant determinants of breast cancer risk. The age-adjusted incidence of breast cancer rises steadily as women grow older, reflecting cumulative genomic damage, prolonged hormonal exposure, and age-related changes in breast tissue architecture [4]. Gender is similarly crucial, as the overwhelming majority of breast cancers occur in women due to the influence of estrogen and progesterone on breast epithelial cells, although men can also develop the disease at much lower rates. Personal medical history is another important contributor; women who have been diagnosed with breast cancer in one breast have a significantly increased risk of developing a second primary tumor in the contralateral breast, a pattern attributed to shared genetic susceptibility and the persistence of high-risk tissue changes [5].

Histologic abnormalities discovered through breast biopsy provide one of the strongest predictors of future breast cancer risk and represent an essential diagnostic category. Conditions such as lobular carcinoma in situ (LCIS) and proliferative lesions with atypia—most notably atypical ductal hyperplasia and atypical lobular hyperplasia—are associated with substantially elevated lifetime risk, often necessitating closer surveillance and consideration of chemoprevention [4]. In addition to histologic features, family history plays an essential role in risk assessment. First-degree relatives of patients with breast cancer exhibit a two- to threefold increase in risk, and this familial tendency is frequently linked to inherited genetic mutations. Although hereditary breast cancer accounts for only about 5% to 10% of all cases, it is significantly overrepresented in younger women, comprising up to 25% of cases in women under 30. Mutations in BRCA1 and BRCA2 remain the most well-known and clinically impactful genetic alterations, profoundly increasing the lifetime risk of both breast and ovarian cancers [5]. Reproductive history further influences risk by modulating cumulative estrogen exposure throughout a woman's life. Early menarche before age 12, late menopause after age 55, nulliparity, and having the first full-term pregnancy after age 30 are all associated with prolonged or intensified exposure to estrogen, which increases the likelihood of malignant transformation in breast epithelial cells [4]. Similarly, exogenous hormonal exposure—including oral contraceptives in premenopausal women and hormone replacement therapy in postmenopausal women—can slightly elevate risk, particularly when combined estrogen-progesterone regimens are used for extended durations

[5]. Other influential factors include ionizing radiation exposure, which is particularly relevant in individuals who received therapeutic chest irradiation during adolescence or early adulthood. Environmental and lifestyle contributors also play a meaningful role; obesity, especially after menopause, increases estrogen levels through peripheral conversion in adipose tissue, while excessive alcohol consumption has been consistently linked to elevated breast cancer risk through hormonal and metabolic pathways [4],[5]. Collectively, these risk factors underscore the need for a multifaceted, personalized approach to breast cancer prevention and screening, integrating biological, behavioral, and social dimensions to optimize long-term health outcomes for women.



Fig. 1: Common sites of breast cancer metastasis.

Epidemiology

Invasive breast cancer remains the most common cancer affecting women across the globe, accounting for approximately 11.7% of all newly diagnosed cancer cases in 2020 and representing a critical public health concern in both developed and developing regions [6]. Breast cancer incidence is strongly age-dependent, illustrating a clear upward trajectory as women grow older. In the United States, it is estimated that 1 in 8 women will develop breast cancer at some point during their lifetime, while men, although significantly less affected, face a lifetime risk of approximately 1 in 1000, underscoring that breast cancer is not exclusively a female disease [7][8][9]. Age-stratified incidence data demonstrate a steep rise from just 1.5 cases per 100,000 women aged 20 to 24 to a peak of 421.3 cases per 100,000 among women aged 75 to 79. Notably, 95% of all newly diagnosed breast cancer cases occur in women aged 40 years or older, and the median age at diagnosis is 61, reflecting the cumulative nature of hormonal, genetic, and environmental influences over the lifespan [6]. Historically, a rapid increase in breast cancer incidence was observed through the late twentieth century, with steady rises until around the year 2000. Following this period, incidence rates began to decline, particularly among women younger than 50 years. Several factors likely contributed to this shift, including changes in the use of hormone replacement therapy, increased awareness, and improvements in early detection. Over the past 25 years, breast cancer mortality has significantly decreased in North America and parts of Europe due to advances in screening, diagnostic imaging, systemic therapy, and individualized treatment strategies. In the United States alone, breast cancer–related mortality decreased by approximately 43% between 1980 and 2020, a remarkable achievement attributable to both therapeutic innovations and earlier detection through screening programs [6].

However, this favorable trend is not uniform globally. Many African and Asian countries, such as Uganda, South Korea, and India, continue to experience rising incidence and mortality rates. These increases reflect disparities in access to early detection, limited breast cancer screening infrastructure, diagnostic delays, and constrained availability of comprehensive treatment modalities. Within the United States as well, significant disparities persist based on race, ethnicity, and socioeconomic status. Although non-Hispanic white women exhibit the highest incidence rate at 128.1 per 100,000, African American women experience disproportionately higher mortality, highlighting gaps in access to care, timely diagnosis, and treatment effectiveness [10]. Hispanic/Latina women have an incidence rate of 91.0 per 100,000, American Indian/Alaska Native women 91.9 per 100,000, and Asian American/Pacific Islander women 88.3 per 100,000, reflecting diversity in risk profiles, cultural influences, and health system access across different demographic groups [10]. As such, the epidemiology of breast cancer underscores an ongoing need for equity-focused public health interventions, enhanced screening accessibility, and continued global investment in cancer control strategies.

Pathophysiology

The pathophysiology of breast cancer reflects a multifaceted and dynamic process in which genetic alterations, hormonal influences, microenvironmental factors, and lifestyle exposures interact to drive oncogenesis. The vast majority of breast cancer cases—approximately 90% to 95%—are considered sporadic, meaning they arise without a clearly identifiable hereditary mutation, while only 5% to 10% of patients harbor a documented genetic predisposition [11]. Among these hereditary forms,

BRCA1 and BRCA2 mutations are the most well-established and clinically significant, conferring a markedly increased lifetime risk for both breast and ovarian cancers. These mutations compromise DNA repair mechanisms, particularly homologous recombination, leading to genomic instability and facilitating malignant transformation. Invasive ductal carcinoma and invasive lobular carcinoma constitute the two most common pathological subtypes of invasive breast cancer. Invasive ductal carcinoma originates from the epithelial lining of the lactiferous ducts and accounts for the majority of cases, whereas invasive lobular carcinoma arises from the lobules and often displays a distinctive growth pattern characterized by reduced cell cohesion and diffuse infiltration. The progression of breast carcinogenesis is not solely determined by histologic origin but involves complex interactions among genetic mutations, hormonal and reproductive factors, cumulative estrogen exposure, and environmental influences. Estrogen and progesterone signaling play pivotal roles in stimulating proliferation of breast epithelial cells, thereby creating opportunities for genetic errors to accumulate and promoting cellular environments susceptible to transformation.

Advances in breast cancer genomics have led to the molecular classification of tumors into biologically distinct subtypes with important prognostic and therapeutic implications. These molecular subtypes include luminal A, luminal B, basal-like, and HER2-enriched disease, each defined by variations in hormone receptor status and human epidermal growth factor receptor 2 (HER2) expression. Luminal A tumors are hormone receptor–positive and HER2-negative, typically presenting with slower proliferation rates and demonstrating favorable outcomes with excellent survival [12]. Luminal B tumors are also hormone receptor–positive but exhibit HER2 positivity or higher proliferative activity, resulting in a more aggressive clinical course than luminal A tumors while still responding to endocrine therapies. HER2-enriched tumors, characterized by HER2 positivity and absence of hormone receptors, historically demonstrated aggressive behavior and poor prognosis. However, the advent of targeted anti-HER2 therapies, such as trastuzumab, significantly transformed outcomes and redefined the treatment landscape for these patients [13]. Basal-like tumors—frequently synonymous with triple-negative breast cancer—lack expression of both hormone receptors and HER2. They are associated with rapid progression, limited targeted treatment options, and comparatively poor survival [14]. Overall, the pathophysiology of breast cancer reflects a heterogeneous disease process in which molecular subtype is central to guiding treatment decisions, predicting prognosis, and personalizing therapeutic strategies [14].

Histopathology

The histopathology of invasive breast cancer encompasses a wide spectrum of morphologic patterns, molecular features, and biologic behaviors that together guide diagnosis, prognosis, and treatment selection. Invasive breast cancer is defined by the spread of malignant epithelial cells beyond the basement membrane into the surrounding stroma, where they can access lymphatic and vascular channels and ultimately metastasize. Histologic evaluation remains one of the cornerstones of breast cancer characterization, providing essential information about tumor subtype, hormone receptor expression, cellular proliferation, and structural architecture. All invasive breast cancer specimens undergo routine testing for estrogen receptor (ER), progesterone receptor (PR), and HER2 receptor status, as these biomarkers critically influence therapeutic strategies and clinical outcomes. Additional microscopic parameters assessed include tumor grade, nuclear pleomorphism, mitotic activity, Ki-67 proliferation index, desmoplastic response, tumor necrosis, the presence of multifocal or multicentric disease, and identification of associated premalignant lesions such as ductal carcinoma in situ (DCIS). The most common histologic form of invasive breast cancer is invasive ductal adenocarcinoma, also referred to as invasive ductal carcinoma of no special type. This subtype represents approximately 50% to 75% of all invasive cases and is frequently detected clinically as a palpable mass due to a pronounced desmoplastic stromal reaction [1]. Microscopically, invasive ductal carcinoma arises from the terminal duct-lobular unit, where malignant epithelial cells exhibit variable degrees of atypia and invade the basement membrane into adjacent tissues. Despite its high prevalence, invasive ductal carcinoma does not possess a single pathognomonic histologic pattern; instead, it presents with diverse architectural arrangements, including glandular, solid, trabecular, and mixed patterns, with degrees of differentiation ranging from well-formed tubules to sheets of pleomorphic cells.

Invasive lobular carcinoma represents the second most common subtype, accounting for roughly 10% to 15% of invasive breast cancers. This subtype is characterized histologically by small, discohesive tumor cells arranged in a single-file pattern as they infiltrate breast stroma, a consequence of loss of the adhesion molecule E-cadherin, which is typically negative on immunohistochemical staining [15]. Clinically, invasive lobular carcinoma poses diagnostic challenges because it infiltrates the breast in a diffuse manner, often without forming a well-defined mass. As a result, these tumors frequently escape detection on mammography and may remain occult until advanced. Bilateral involvement and multifocality are more common in invasive lobular carcinoma compared to ductal carcinoma, further contributing to diagnostic complexity. Mucinous

carcinoma, also known as colloid carcinoma, constitutes approximately 2% to 5% of breast cancers and is more frequently observed in older women [16]. These tumors are characterized by abundant extracellular mucin production, which imparts a gelatinous appearance on gross examination and distinct pools of mucin containing clusters of malignant cells on microscopy. Mucinous carcinomas generally have a favorable prognosis, particularly when they occur in pure rather than mixed forms. Tubular carcinoma accounts for about 1% to 2% of all invasive breast cancers and is associated with an excellent prognosis [16]. Microscopically, these tumors are composed of well-formed angulated tubules lined by a single layer of epithelial cells with minimal atypia and low mitotic activity. Their deceptively benign appearance underscores the importance of histopathologic expertise in differentiating tubular carcinoma from benign sclerosing lesions.

Medullary carcinoma represents a rare but clinically significant subtype characterized by poorly differentiated, high-grade tumor cells with syncytial growth patterns, prominent nucleoli, and dense lymphoplasmacytic infiltration of the surrounding stroma [17]. These tumors occur more frequently in younger patients and those with BRCA1 mutations, reflecting their association with basal-like molecular profiles. Despite their aggressive histology, certain forms of medullary carcinoma may have relatively favorable outcomes due to their strong immune response, though classification remains challenging. Collectively, the histopathologic diversity of invasive breast cancer underscores the essential role of microscopic examination in accurately categorizing tumors, tailoring therapeutic decisions, and predicting clinical behavior. The integration of histology with molecular and receptor profiling forms the foundation of modern personalized breast cancer management [17].

History and Physical

A careful and structured approach to history taking and physical examination is fundamental in the evaluation of patients for breast cancer. The American College of Obstetricians and Gynecologists (ACOG) recommends a periodic review of patient history specifically for breast cancer risk assessment, emphasizing that risk evaluation is not a one-time event but an ongoing process integrated into routine women's health care [18]. Clinicians are encouraged to use validated online risk assessment tools to estimate an individual woman's probability of developing breast cancer, incorporating factors such as age, family history, reproductive history, prior biopsies, and genetic predisposition [18]. This risk stratification helps guide decisions regarding the timing and modality of screening, the need for genetic counseling, and the intensity of clinical surveillance. Most patients with breast cancer are asymptomatic at the time of diagnosis, with lesions frequently detected incidentally during routine screening mammography or clinical breast examinations. In this context, the patient's history may initially be unremarkable, highlighting the importance of adhering to age-appropriate screening recommendations. As a breast lesion enlarges, the patient may become aware of a palpable mass, typically described as a firm, non-tender, and often fixed lump in the breast [19]. Breast pain, or mastalgia, is a relatively uncommon presenting symptom in malignancy, accounting for only a small minority of cases, and most breast pain is ultimately due to benign causes [19]. Nevertheless, new, persistent, or focal breast pain warrants evaluation, especially when associated with other concerning features. More advanced breast cancer may manifest with striking local or systemic symptoms. Locally, patients may notice changes in breast contour, skin thickening, or the classic peau d'orange appearance caused by lymphatic obstruction. Ulceration or fungating masses may develop in neglected or aggressive tumors. Axillary lymphadenopathy can present as palpable lumps in the axilla, sometimes predating or overshadowing the primary breast lesion [20]. Signs of distant metastasis—such as bone pain, weight loss, dyspnea, or neurological symptoms—may also be present in more advanced disease. Inflammatory breast cancer, a particularly aggressive and advanced form, often mimics infectious or inflammatory conditions of the breast, including mastitis or breast abscess, presenting with diffuse redness, warmth, swelling, and tenderness. This resemblance may lead to initial misdiagnosis and delay in appropriate oncologic evaluation if the possibility of malignancy is not considered [20].



Fig. 2: Breast Mammogram. A mammographic view of the left breast demonstrates skin thickening,

diffusely increased breast density, and malignant-type calcifications in this patient with biopsy-proven inflammatory breast cancer.

The physical examination remains a vital component of clinical assessment even in the era of advanced imaging. A thorough breast examination should be conducted with the patient in multiple positions—typically sitting or standing, and supine—to allow optimal visualization and palpation of all quadrants of the breast and axillary tail. The arms should be positioned in various maneuvers, including abduction, extension, and external rotation, to accentuate subtle asymmetries or retractions. The examiner should carefully inspect for skin changes, including erythema, dimpling, edema, peau d'orange, nipple retraction, or ulceration, and assess for any spontaneous or expressible nipple discharge, noting its color and character [21]. Systematic palpation of each breast using the pads of the fingers, in vertical strip, radial, or concentric circular patterns, helps ensure that all regions are evaluated. Palpation of regional lymph node basins—including axillary, supraclavicular, and infraclavicular nodes—is essential to assess for lymphadenopathy, which can influence staging and management decisions. Professional societies differ somewhat in their recommendations regarding routine clinical breast examinations in asymptomatic, average-risk women. The American Cancer Society has moved away from recommending routine clinical breast examinations for low-risk, asymptomatic women, citing limited evidence of mortality benefit. In contrast, ACOG allows that clinical breast examinations may be offered to these women as part of shared decision-making, recommending an interval of every 1 to 3 years for women aged 25 to 39 years and annually for women aged 40 years and older when screening examinations are performed [18]. Regardless of these differences, there is broad consensus that women at high risk for breast cancer, as well as any symptomatic woman, should always undergo a targeted and meticulous clinical breast examination as part of their evaluation [18],[21].

Evaluation

Diagnostic Breast Imaging

The evaluation of suspected breast cancer relies heavily on high-quality diagnostic breast imaging, which serves both as a screening tool in asymptomatic women and as a diagnostic modality in those with clinical abnormalities. Mammography remains the most commonly used and most widely available imaging technique for both screening and diagnostic purposes and has been instrumental in the early detection of breast cancer and reduction of disease-specific mortality [22]. Standard screening mammography typically employs two views of each breast and can reveal a range of abnormal findings, including discrete mass lesions, clusters or patterns of microcalcifications, and more subtle architectural distortions that may indicate an underlying malignancy. When an abnormality is identified on screening mammography, diagnostic mammography is performed, utilizing additional targeted and higher-resolution views to better characterize the lesion, refine its location, and determine the need for further assessment [22]. Despite its central role, mammography has limitations. Its sensitivity decreases in patients with markedly dense breast tissue, a situation more common in younger women, where the radiodense parenchyma can obscure small lesions. Mammography may also be challenging in individuals who are unable to tolerate the necessary breast compression due to pain or physical limitations. In these scenarios, adjunctive modalities such as breast ultrasound or contrast-enhanced magnetic resonance imaging (MRI) are often employed [23]. Ultrasound is particularly useful for distinguishing cystic from solid lesions, characterizing palpable abnormalities not well seen on mammography, and guiding percutaneous biopsies. Its sensitivity is generally comparable to that of mammography in many clinical contexts, especially in dense breasts, and it lacks ionizing radiation [23].



Fig. 3: Breast Estrogen Receptor Staining.

Breast MRI, especially when performed with contrast enhancement, is the most sensitive imaging technique available for breast cancer detection. It is highly effective in revealing multifocal, multicentric, and contralateral disease and in evaluating the extent of tumor involvement, although its specificity may be lower, and it can generate false-positive findings [23]. MRI is time-consuming, costly, and not universally available, which restricts its use to specific indications rather than as a routine screening modality for average-risk women. Commonly accepted indications for breast MRI include evaluation of axillary metastases when no primary breast lesion is identified on conventional imaging (occult primary cancer), assessment of disease extent in Paget disease of the nipple, characterization of multifocal or bilateral cancers, monitoring tumor response to neoadjuvant chemotherapy, and screening of women at very high risk due to strong family history or known genetic mutations such as BRCA1 or BRCA2 [24]. To standardize the interpretation and reporting of breast imaging findings, the Breast Imaging Reporting and Data System (BI-RADS) was developed and is now widely used across imaging modalities [25]. BI-RADS

categories range from 0 to 6 and link imaging appearances to an estimated probability of malignancy in order to guide management. A BI-RADS 0 assessment indicates that the study is incomplete and additional imaging is required, whereas BI-RADS 1 signifies a negative examination with no abnormal findings, and BI-RADS 2 denotes clearly benign findings; in both BI-RADS 1 and 2, routine screening at normal intervals is recommended, with the probability of cancer being essentially zero [25]. BI-RADS 3 lesions are considered probably benign, with less than a 2% likelihood of malignancy, and the recommended management is short-interval follow-up imaging, typically in 6 to 12 months, rather than immediate biopsy. BI-RADS 4 lesions are characterized as suspicious abnormalities and are subdivided into 4A, 4B, and 4C, reflecting increasing levels of concern; overall, these lesions carry a 2% to 95% risk of malignancy, and tissue diagnosis via biopsy is generally advised [25]. BI-RADS 5 indicates imaging findings that are highly suggestive of malignancy, with a greater than 95% probability of cancer, and biopsy is strongly recommended. BI-RADS 6 is reserved for lesions already proven malignant on prior biopsy and is used primarily in the context of treatment planning and follow-up [25].



Fig. 4: Breast Cancer Fine Needle Aspiration Cytology.

Tissue Biopsy

Once imaging identifies a lesion that is suspicious for malignancy—typically BI-RADS 4 or 5—definitive diagnosis requires tissue sampling. Image-guided core needle biopsy has become the standard of care for histologic confirmation and is generally preferred over fine needle aspiration due to its superior diagnostic yield and capacity to provide sufficient tissue for receptor and molecular studies [26][27][28]. Stereotactic guidance is often used for lesions seen only on mammography, such as microcalcifications or subtle architectural distortions, whereas ultrasound guidance is utilized when the lesion is visible on ultrasound. Core needle biopsy permits evaluation of tumor type, grade, and key biomarkers, and reduces the need for diagnostic open surgical biopsies [29]. In patients with clinically or radiologically suspicious regional lymphadenopathy, particularly in the axilla, ultrasound-guided core needle biopsy of lymph nodes is recommended to confirm metastatic involvement before definitive surgery or systemic therapy [26]. During both breast and nodal biopsies, radiopaque or MRI-compatible markers (clips) are commonly placed at the biopsy site. These markers are invaluable in localizing the lesion for subsequent surgery or targeted radiation, especially if the lesion responds to neoadjuvant therapy and becomes less conspicuous on imaging. All biopsy specimens must be submitted for histopathologic evaluation, including routine assessment of estrogen receptor, progesterone receptor, and HER2 status, as well as other markers as appropriate, since these results directly inform systemic treatment decisions, particularly endocrine and targeted therapies [29].



Fig. 5: Invasive Ductal Carcinoma. Histological slide of high-grade ductal carcinoma in situ with invasive ductal carcinoma.

Staging Imaging

After histologic confirmation of breast cancer, the extent of disease must be assessed to guide treatment planning. For patients with early-stage, operable breast cancer and no symptoms suggestive of distant metastases, extensive systemic staging with routine laboratory and imaging tests is generally not recommended, as the yield is low and does not improve outcomes [30]. In such cases, the primary focus is on local and regional evaluation through breast imaging and clinical examination. However, when patients exhibit clinical features or symptoms that raise concern for metastatic spread—such as unexplained bone pain, respiratory symptoms, neurologic deficits, or abnormal liver function tests—targeted staging investigations are warranted. Depending on the symptom profile, this may include MRI of the brain, chest computed tomography (CT), bone scintigraphy, or CT of the abdomen and pelvis [30]. For patients in whom neoadjuvant chemotherapy is planned, baseline laboratory studies, including a complete blood count and a comprehensive metabolic panel with liver function tests, are essential to evaluate

organ function and establish reference values prior to initiating systemic treatment [30]. In the setting of clinically advanced breast carcinoma, such as inflammatory breast cancer, tumors with direct involvement of the chest wall or skin, or bulky and fixed axillary lymphadenopathy, more extensive systemic staging is indicated due to the higher likelihood of distant disease. In these cases, CT scanning of the chest, abdomen, and pelvis is commonly combined with a bone scan or integrated fluorodeoxyglucose positron emission tomography (FDG-PET) to assess for metastasis in bone, liver, lung, and other sites [30]. The results of staging imaging are critical in determining whether curative-intent surgery and radiotherapy are appropriate or whether the disease should be approached with primarily systemic or palliative strategies. Taken together, diagnostic imaging, tissue biopsy, and selective staging investigations form a comprehensive and rational framework for the evaluation of suspected and confirmed breast cancer.

Treatment / Management

Breast cancer treatment is complex and highly individualized, reflecting differences in disease stage, histopathologic and molecular characteristics, patient comorbidities, personal preferences, and local resource availability. Broadly, management strategies are divided into approaches for early breast cancer, locally advanced breast cancer (LABC), and metastatic breast cancer, each with distinct goals and therapeutic combinations of surgery, systemic therapy, and radiation [30]. Early and locally advanced disease are treated with curative intent, whereas metastatic breast cancer is generally approached as a chronic, incurable condition in which the focus is on prolonging survival and optimizing quality of life. (A1)

Early Breast Cancer

Early breast cancer usually refers to tumors less than 5 cm in size without clinically positive lymph nodes. The principal aim in this setting is definitive local control of the primary tumor and regional lymph nodes, alongside eradication of micrometastatic disease through systemic therapy. Treatment typically incorporates surgery, systemic chemotherapy, radiation therapy, and endocrine therapy where indicated, guided by tumor stage and molecular profile [30]. (A1) Surgical management of the primary tumor consists either of breast-conserving surgery (BCS), such as lumpectomy or partial mastectomy, or total mastectomy. The choice depends on tumor size and location, breast size, multifocality, patient preference, and the feasibility of achieving negative margins while maintaining acceptable cosmetic outcomes. For many patients with early-stage disease, BCS followed by whole-breast irradiation provides local control and survival outcomes equivalent to mastectomy, making it a preferred option when technically and oncologically appropriate [30]. Axillary lymph node evaluation is an integral component of surgical treatment. Sentinel lymph node biopsy is the standard approach in clinically node-negative patients and is performed at the time of primary surgery. When only two to three sentinel nodes contain microscopic metastases and there is no extranodal extension, further axillary surgery can often be safely omitted. In contrast, patients with more than three positive nodes or with extranodal extension generally require completion of axillary lymph node dissection or comprehensive axillary radiation to reduce regional recurrence risk [30].

Systemic chemotherapy in early breast cancer is recommended based on pathologic stage and tumor biology. In hormone receptor–positive tumors, the decision to administer chemotherapy is increasingly supported by multigene genomic assays, such as commercially available tests like Oncotype Dx, which stratify patients into low-, intermediate-, and high-risk groups for recurrence [30]. High-risk hormone receptor–positive patients derive significant benefit from chemotherapy in addition to endocrine therapy, whereas many low-risk patients can safely forgo chemotherapy. For HER2-positive tumors larger than 1 cm, anti-HER2–directed therapy, combined with appropriate chemotherapy, is recommended because of the substantial survival advantage conferred by targeted agents in this subgroup [30]. Similarly, all triple-negative breast cancers (TNBC) greater than 1 cm in size are typically treated with systemic chemotherapy, given the aggressive nature of these tumors and the absence of hormone or HER2 targets. Radiation therapy plays a vital role in local control. All patients undergoing BCS should receive adjuvant radiation to the remaining breast tissue, including a boost to the tumor bed, to minimize the risk of local recurrence [30]. Patients treated with total mastectomy generally do not require chest wall irradiation unless they exhibit high-risk features, such as primary tumors larger than 5 cm, involvement of the chest wall or skin, multifocal disease, or the presence of four or more positive axillary lymph nodes. In these settings, postmastectomy radiation therapy significantly reduces locoregional recurrence and can improve survival.

Endocrine (hormonal) therapy is indicated for all hormone receptor–positive breast cancers, regardless of patient age or nodal status. Premenopausal women are typically treated with tamoxifen, with or without ovarian function suppression in higher-risk cases, whereas postmenopausal women usually receive aromatase inhibitors. Endocrine therapy reduces recurrence risk and improves survival and is often administered for at least five years, with extended duration considered in selected high-risk patients [30]. Up-front, or neoadjuvant, chemotherapy is increasingly used even in early-stage triple-negative and HER2-positive tumors. Delivering systemic therapy before surgery offers several advantages: it allows clinicians to assess in vivo chemosensitivity, increases the likelihood of

completing the planned systemic regimen, and can downstage the tumor, thereby enhancing the feasibility of breast conservation [31][32]. Pathologic complete response after neoadjuvant therapy is an important prognostic marker and may inform subsequent systemic treatment decisions in these biologically aggressive subtypes. (A1)

Locally Advanced Breast Cancer (LABC)

Locally advanced breast cancer typically encompasses tumors larger than 5 cm, those with clinically positive lymph nodes, or those involving the chest wall or skin in the absence of distant metastases. These tumors require a multimodal approach, with neoadjuvant systemic therapy almost always playing a central role, followed by surgery and radiation therapy. Patients with LABC commonly undergo baseline breast MRI to delineate the extent of disease and to assess multifocal or multicentric involvement [30]. Before initiating neoadjuvant chemotherapy, radiographically detectable markers (clips) are placed within the primary tumor and any involved lymph nodes. This is crucial because tumors can markedly shrink or even become radiologically occult after treatment; the markers guide surgeons in accurately localizing and excising the original sites of disease [30]. (A1) Neoadjuvant chemotherapy regimens in LABC are tailored based on tumor subtype (hormone receptor–positive, HER2-positive, or triple-negative), patient age, performance status, and available drugs [30]. The goals are to reduce tumor size to facilitate resectability or permit BCS, eradicate micrometastatic disease early, and provide biological insight into tumor behavior by observing the degree of treatment response. After completion of neoadjuvant therapy, repeat imaging of the breast and axilla is performed to quantify tumor regression and guide the subsequent surgical plan. Surgical options following neoadjuvant therapy remain BCS or total mastectomy, selected according to residual tumor size, distribution, and patient preference. Contraindications to BCS in this setting include persistently large tumors relative to breast size, chest wall or skin involvement, multifocal disease not amenable to single-field resection, inability to receive postoperative radiation, or unfavorable tumor-to-breast size ratios [30]. Axillary management in LABC reflects the higher baseline risk of nodal involvement. In patients who present with clinically positive axillary lymph nodes, a full axillary lymph node dissection is generally required at the time of surgery, irrespective of the apparent nodal response to chemotherapy. In those with a clinically negative axilla at presentation, sentinel lymph node biopsy is performed, and at least three nodes should be harvested using dual-tracer techniques to minimize false-negative rates. If residual nodal disease is identified, completion axillary dissection or comprehensive axillary radiation is indicated [30]. Patients with residual disease after neoadjuvant chemotherapy, particularly in aggressive subtypes such as TNBC or HER2-positive disease, may benefit from additional adjuvant systemic therapy tailored to the molecular profile and response pattern. Radiation therapy is almost always indicated in LABC, whether the patient undergoes BCS or mastectomy, given the high risk of locoregional recurrence. Endocrine therapy is prescribed for all hormone receptor–positive tumors following surgery and chemotherapy, according to menopausal status and risk profile, as in early-stage disease [30].

Metastatic Breast Cancer

Metastatic breast cancer, defined by the presence of distant organ involvement, is managed primarily with systemic therapy, as curative treatment is rarely achievable. The objectives in this setting are to prolong survival, control symptoms, preserve organ function, and maintain quality of life. Treatment choice is driven predominantly by tumor biology—hormone receptor status, HER2 expression, and other molecular features—as well as by patient performance status and prior therapies [33]. For hormone receptor–positive, HER2-negative metastatic disease, endocrine therapy is usually the backbone of treatment, often combined with targeted agents such as CDK4/6 inhibitors, depending on availability and prior exposure. Chemotherapy is reserved for patients with endocrine-refractory disease or those with rapidly progressive, life-threatening visceral metastases. In HER2-positive metastatic breast cancer, anti-HER2–directed regimens are central, commonly combining targeted agents with chemotherapy. Triple-negative metastatic disease is primarily treated with chemotherapy, though subsets of patients may benefit from immunotherapy or other targeted strategies depending on biomarker status and drug access. Palliative radiation therapy is frequently employed to control symptoms from bulky primary tumors, painful bone metastases, brain metastases, or threatening local complications such as spinal cord compression or airway obstruction. Surgery in the metastatic setting is generally limited to palliation—for example, controlling bleeding or infection from a fungating breast mass or stabilizing impending fracture—and is not routinely performed for curative purposes [33]. Supportive and palliative care services, including psychosocial, nutritional, and symptom-focused interventions, are integral throughout the course of metastatic disease, reflecting the overarching goal of maximizing patient comfort and dignity.

Differential Diagnosis

The differential diagnosis of breast cancer encompasses several benign and inflammatory conditions that may closely mimic malignant disease both clinically and radiographically. Because early detection of breast cancer significantly improves outcomes, distinguishing between malignant and non-malignant breast conditions is a critical component of clinical evaluation. Many breast abnormalities present with overlapping features—such as palpable masses,

localized tenderness, skin changes, or radiologic opacities—and careful assessment is required to avoid misdiagnosis. A thorough history, detailed clinical breast examination, and appropriate imaging are essential, and in many cases, tissue biopsy remains the definitive method of differentiation. One of the most frequently encountered mimics of breast cancer is mastitis or breast abscess. Mastitis typically presents erythema, warmth, pain, and swelling of the affected breast, findings that can resemble those of inflammatory breast cancer. Inflammatory breast cancer often develops rapidly, with diffuse edema and characteristic peau d'orange appearance, features that overlap with acute infection. However, mastitis typically responds to antibiotic therapy, whereas inflammatory breast cancer does not. Therefore, any presumed infection that fails to improve with appropriate antimicrobial treatment should prompt further diagnostic workup, including imaging and possible biopsy, to rule out underlying malignancy. This distinction is especially important in non-lactating women, in whom mastitis is less common and a higher degree of suspicion is warranted.

Fat necrosis is another important differential diagnosis. It often occurs following trauma, surgery, or radiation therapy to the breast. The inflammatory response to adipocyte injury can lead to firm palpable masses, architectural distortion, or calcifications on imaging—features that closely resemble breast cancer. Clinically, fat necrosis may present as a hard, irregular mass, sometimes with associated skin retraction or tenderness, further complicating the differentiation from malignancy. Imaging findings may include oil cysts, coarse calcifications, or spiculated masses, and because of these variable patterns, fat necrosis frequently necessitates biopsy to confirm its benign nature. Fibroadenoma is a common benign tumor of the breast, particularly in younger women. It typically presents as a well-circumscribed, mobile, and non-tender mass. While classic fibroadenomas have characteristic imaging features that allow confident diagnosis, larger lesions—particularly those greater than 2 cm—may raise concern for phyllodes tumors or obscure coexisting malignancy. For this reason, excisional biopsy is often recommended for rapidly enlarging or atypical fibroadenomas to ensure accurate diagnosis and to exclude invasive cancer. Collectively, the differential diagnosis of breast cancer requires careful clinical judgment, correlation with imaging findings, and, in many cases, pathologic confirmation. Maintaining a broad differential and recognizing benign conditions that mimic malignancy are essential steps in ensuring that breast cancer is neither overlooked nor over diagnosed.

Surgical Oncology

Surgery remains a cornerstone in the multidisciplinary management of breast cancer and continues to play a central role despite remarkable advances in systemic chemotherapy, endocrine therapy, and targeted biologic agents [30]. Modern systemic treatments have allowed breast operations to become less radical and morbid compared with historical procedures, while overall survival and local control have improved. In contemporary practice, the goals of breast cancer surgery are twofold: to achieve durable local-regional disease control through complete resection of the primary tumor and involved lymph nodes, and to provide accurate pathologic staging that guides subsequent systemic and radiation therapy [30]. Surgical planning is individualized, considering tumor size and location, biologic subtype, the presence or absence of nodal involvement, patient anatomy and preferences, and the feasibility of adjuvant radiation. Breast-conserving surgery (BCS) can be offered to most patients with tumors less than 5 cm in greatest diameter, provided that the breast is sufficiently large to accommodate an adequate oncologic resection with acceptable cosmesis [30]. Achieving negative margins is essential, and postoperative radiation therapy is mandatory to minimize local recurrence. Mastectomy is indicated for large primary tumors that are disproportionate to breast size, tumors with direct invasion of the skin or chest wall, multifocal or multicentric disease not amenable to single-field resection, inflammatory breast cancer, and in patients who cannot receive radiation, whether due to prior irradiation, connective tissue disease, or other contraindications [30]. Axillary management is integral to surgical oncology. Sentinel lymph node biopsy has become the standard staging procedure for patients with clinically node-negative axillae and has substantially reduced the need for full axillary lymph node dissection, thereby decreasing the risk of lymphedema and shoulder dysfunction [34]. Patients with one to three microscopic sentinel node metastases without gross extranodal extension can often safely avoid completion dissection, while those with clinically positive axillary nodes at presentation typically require formal axillary lymph node dissection [34].

A partial mastectomy or lumpectomy is the foundational operation of breast-conserving therapy. This procedure involves excision of the tumor with a rim of surrounding normal breast tissue to ensure clear margins while maintaining breast shape [35]. The choice and orientation of the incision are tailored to the tumor's location and the goal of optimizing cosmetic outcome. Commonly used incision patterns include circumareolar, radial, or those aligned with natural skin creases of the breast to minimize visible scarring [35]. The volume of tissue removed relative to the overall breast size, as well as the preservation and position of the nipple-areolar complex, are major determinants of final cosmetic results. For nonpalpable lesions, preoperative localization is essential to guide precise resection. This can be achieved through wire localization, radioactive seed localization, or other image-guided localization techniques to ensure that the nonpalpable tumor and any associated microcalcifications are completely

removed. Simple mastectomy entails complete removal of the breast parenchyma along with the nipple-areolar complex, usually including the underlying pectoralis major fascia but preserving the pectoralis major muscle itself [34]. The extent of skin removal can be varied depending on whether immediate or delayed reconstruction is planned and which reconstructive technique will be used. In skin-sparing mastectomy, most of the breast skin envelope is preserved to facilitate reconstruction. Nipple-sparing mastectomy is a more recent evolution of the simple mastectomy in which the nipple-areolar complex is retained while the glandular breast tissue is removed through a carefully placed circumareolar or inframammary incision [34]. This approach offers superior cosmetic and psychological outcomes for many patients, as preservation of the nipple-areolar complex more closely maintains the natural appearance of the breast. Oncologic safety depends on appropriate patient selection and intraoperative or pathologic assessment of retroareolar tissue. While nipple-sparing procedures may carry a slightly higher risk of local recurrence compared with traditional mastectomy, outcomes are generally acceptable in properly selected patients.

Modified radical mastectomy combines simple mastectomy with axillary lymph node dissection in a single operation [34]. The incision for the mastectomy is extended laterally to allow comprehensive removal of axillary contents. This procedure provides definitive local control in patients with significant axillary disease and is still required for many with clinically positive nodes, particularly when neoadjuvant therapy does not normalize nodal status. The classic radical mastectomy, which additionally removes the pectoralis major and minor muscles and often sacrifices critical nerves, is now rarely performed due to significant morbidity and the absence of survival benefit compared to less extensive operations. Axillary surgery itself encompasses sentinel lymph node biopsy and axillary lymph node dissection. The axillary lymph nodes, which drain much of the ipsilateral breast, are anatomically divided into three levels by their relationship to the pectoralis minor muscle. Sentinel lymph node biopsy is based on the concept that one or a few “sentinel” nodes receive the initial lymphatic drainage from the primary tumor site and thus are most likely to harbor metastases if nodal spread has occurred [36]. A radiotracer, blue dye, or a combination of both is injected near the primary tumor or in the subareolar region. The lymphatic mapping allows the surgeon to identify between one and three nodes that demonstrate the highest uptake of tracer or are visibly stained blue; these nodes are then excised and subjected to pathologic examination [36]. When BCS is performed, the sentinel node biopsy can often be completed through the same incision, although a separate axillary incision near the hair-bearing area may be required in some cases. Axillary lymph node dissection involves the removal of fibrofatty tissue and lymph nodes, primarily from levels II and III, while carefully preserving the long thoracic nerve and thoracodorsal nerve to maintain shoulder function and prevent scapular winging [37]. This more extensive operation is associated with higher rates of complications, including chronic lymphedema, sensory changes, reduced shoulder mobility, and neuropathic pain, which is why it is now reserved for patients with clear indications, such as those with bulky nodal disease or persistent nodal involvement after neoadjuvant therapy [34][37]. Overall, the evolution of surgical oncology in breast cancer reflects a paradigm shift from maximally mutilating procedures to tailored, breast-conserving, and function-preserving strategies supported by effective systemic and radiation therapy. Surgical decisions are increasingly guided by tumor biology, response to neoadjuvant treatments, and patient-centered considerations, with the overarching goal of achieving optimal oncologic outcomes while preserving quality of life [30][35].

Radiation Oncology – Summary

Radiation therapy plays a central role in the multidisciplinary management of breast cancer, chiefly in the adjuvant setting to improve local control, but also as an important tool for palliation of symptoms in advanced disease. In early-stage breast cancer, adjuvant radiotherapy after breast-conserving surgery (BCS) reduces the risk of ipsilateral breast recurrence by roughly 50%.[38][39] Although this reduction in local recurrence has not consistently translated into a clear overall survival benefit in low-risk early-stage patients, radiotherapy is an essential component of breast conservation, as it substantially lowers the risk of relapse and the need for further surgery. Radiotherapy can be delivered using external beam radiation, brachytherapy, or a combination of both, with the choice influenced by tumor factors, patient anatomy, logistics, and institutional expertise.[40][41] A subset of carefully selected patients may be eligible for Accelerated Partial Breast Irradiation (APBI), which targets only the region around the lumpectomy cavity rather than the entire breast. The American Society of Radiation Oncologists (ASTRO) has published appropriateness criteria that classify patients as suitable, cautionary, or unsuitable candidates for APBI.[42] APBI can be delivered via surgically implanted single- or multichannel catheter devices connected to an Ir-192 high–dose rate after loader, providing highly conformal brachytherapy to the tumor bed. Alternatively, APBI may be delivered with external beam radiotherapy using surgical clips, coils, or 3D markers to delineate the target. Typical dosing is 34 to 38.5 Gy in 10 fractions, given twice daily over one week, which is significantly shorter than the 3 to 6 weeks required for standard whole breast radiation. Catheter-based APBI may require an additional minor

procedure, but long-term outcomes are favorable, with a 10-year local recurrence rate of about 4.6%.[43]

Whole breast radiotherapy (WBRT) remains the most widely used adjuvant radiation technique in early-stage disease and is a cornerstone of treatment after BCS.[43] It is usually delivered after surgery, and when indicated, after completion of chemotherapy. WBRT is planned to cover all visible breast tissue on CT simulation, typically using 3D conformal techniques that allow careful control of dose distribution. Particular attention is paid to limiting radiation exposure to the ipsilateral lung and heart, especially in left-sided cancers. Standard WBRT regimens range from 40.05 to 50.4 Gy in 15 to 25 fractions, and long-term series report 10-year ipsilateral breast recurrence rates of approximately 3.9%.[43] An additional focused dose, or "boost," to the surgical cavity may be given after WBRT to further reduce local recurrence risk. Randomized trials have shown that a 10 Gy boost improves local control: one study reported a 5-year local recurrence rate of 3.6% with a boost versus 4.5% without, and the EORTC trial demonstrated 10-year local recurrence rates of 6% with a boost compared to 10% without.[44] The benefit of a boost appears greatest in younger women, particularly those under 60 years.[44] Doses typically range from 10 to 16 Gy. However, a boost increases the risk of breast fibrosis and cosmetic changes; severe fibrosis occurred in 4.4% of patients receiving a boost versus 1.6% without in the EORTC trial.[44] Post-mastectomy radiation therapy (PMRT) is indicated for patients at higher risk of locoregional recurrence, including those with nodal involvement after axillary staging, positive margins, or primary tumors larger than 5 cm. PMRT may also be considered in selected patients with central or medial tumors ≥2 cm and high-risk pathological features such as lymphovascular invasion, grade 3 histology, or hormone receptor–negative disease. Treatment fields include the chest wall, with or without regional lymphatics. PMRT has been evaluated extensively in prospective trials, including the Danish 82bc studies, which showed durable reductions in locoregional recurrence and breast cancer mortality and improvements in overall survival for high-risk pre- and postmenopausal patients.[45] Thirty-year follow-up continues to show benefits in overall survival (19% vs 14%), breast cancer mortality (56% vs 67%), and locoregional recurrence (9% vs 37%) with PMRT.[45]

Comprehensive nodal irradiation (CNI) extends coverage to all regional lymphatics draining the breast and chest wall, including levels I to III axillary nodes, supraclavicular nodes, and internal mammary nodes. CNI can be combined with WBRT or PMRT and is generally recommended for node-positive patients identified either on sentinel lymph node biopsy or axillary dissection.[46] In patients who had an axillary dissection, CNI is typically directed to undissected regions and nodal areas at highest risk. Technically, CNI is more complex than WBRT alone, often requiring three- or four-field arrangements, and results in increased radiation dose to the lungs and heart. Advanced techniques such as deep inspiratory breath hold (DIBH) and intensity-modulated radiation therapy (IMRT) can help meet heart and lung dose constraints, particularly in left-sided disease.[47] Trials comparing CNI to axillary dissection in patients with one to three positive nodes have shown similar axillary control (0.93% vs 1.82%), and CNI has been associated with improved 10-year disease-free survival (77% vs 82%), albeit without a clear improvement in overall survival.[46][47] The expanded target volume, however, increases the risk of lymphedema and radiation pneumonitis. IMRT may be used instead of conventional 2D or 3D planning when dose constraints to critical organs, especially the heart, cannot be achieved or when significant dose inhomogeneity threatens cosmesis.[48] Prospective randomized trials have consistently shown lower rates of grade 2 or higher radiation dermatitis with IMRT compared with traditional planning, reflecting improved homogeneity and reduced skin hotspots, without differences in local control or survival.[48][49] Radiation therapy is associated with several potential complications. Cardiac toxicity is a well-recognized late effect, particularly in left-sided treatments, where exposure of coronary arteries can accelerate atherosclerosis. A population-based case-control study demonstrated that the risk of major coronary events increases linearly with mean heart dose, by about 7.4% per gray, with no apparent threshold; women with preexisting cardiac risk factors are at greater risk.[50] Radiation pneumonitis occurs in about 0.8% to 2.9% of patients receiving adjuvant breast irradiation and may present up to a year after treatment.[51] Risk rises with the volume of lung irradiated and is higher when regional nodal fields are included; in the MA.20 study, pneumonitis occurred in 1.2% of patients receiving nodal RT versus 0.2% with breast-only treatment.[47] Concurrent taxane chemotherapy, such as paclitaxel, may further increase pneumonitis risk.[52]

Breast fibrosis is relatively common, with reported incidences of 10% to 15%, and can cause breast shrinkage, induration, pain, and cosmetic distortion.[53] Risk is influenced by dose, heterogeneity, use of a boost, and systemic therapy. A nomogram derived from the EORTC 22881–10882 "Boost versus No Boost" trial can help predict moderate to severe fibrosis.[54] Preventive strategies include careful planning to limit hotspots (<107% of prescription), judicious use of boosts, and, in high-risk patients, post-radiation pentoxifylline with vitamin E, which has shown benefit in small, randomized trials.[55] Established fibrosis is largely irreversible and managed symptomatically. Lymphedema may develop months after treatment, particularly in patients undergoing axillary dissection and regional nodal irradiation. Risk is related to the extent of lymphatic

disruption, number of nodes removed, BMI, and volume of irradiated lymphatics.[56] Sentinel node biopsy alone carries about a 5.6% risk of lymphedema versus 19.9% after full axillary dissection.[57] In the AMAROS trial, 5-year lymphedema rates were 25% with axillary dissection versus 12% with nodal radiation alone.[58] Management includes compression garments, exercise, limb elevation, and infection prevention. Rarer complications include brachial plexopathy, seen in about 1% of patients, typically 8 to 12 months after high-dose regional nodal RT; risk increases with doses above 50 Gy and chemotherapy exposure.[59] Rib fractures occur in 0.3% to 1.8% of patients and are usually managed conservatively.[59][60] Finally, radiation-induced secondary malignancies, including sarcomas and lung or esophageal cancers, are a recognized late risk. Meta-analyses suggest a 1% to 2% absolute risk of non-breast secondary cancers at 10 years, influenced by age, sex, field size, and dose, although this must be weighed against the substantial benefits of radiotherapy in local control and breast preservation.[61][62][63]

Medical Oncology

Medical oncology in breast cancer focuses on systemic therapies that target micrometastatic and overt metastatic disease. The main modalities—cytotoxic chemotherapy, hormonal therapy, targeted therapy, and immunotherapy—are selected based on tumor biology (hormone receptor and HER2 status), stage, patient comorbidities, and anticipated benefit-to-toxicity balance. Together, these treatments have substantially improved overall survival, disease-free survival, and local control across multiple breast cancer subtypes.[64][65] Cytotoxic chemotherapy is used in both the adjuvant and neoadjuvant settings. It is particularly effective in biologically aggressive tumors with high proliferation rates, such as triple-negative and HER2-positive breast cancers.[64] Classic adjuvant regimens included CMF (cyclophosphamide, methotrexate, and 5-fluorouracil), but modern protocols typically incorporate anthracyclines (doxorubicin, epirubicin) and taxanes in combinations such as TAC (docetaxel, adriamycin, and cyclophosphamide).[65] Adjuvant chemotherapy improves overall survival and disease-free survival, while reducing local recurrence, and is recommended for most patients with triple-negative or HER2-positive tumors larger than T1.[65] In hormone receptor (HR)–positive disease, the role of chemotherapy is more individualized and guided by genomic assays such as Oncotype Dx and Mammaprint, which stratify recurrence risk and help identify patients who derive meaningful benefit from chemotherapy versus endocrine therapy alone.[66][67] Neoadjuvant chemotherapy is increasingly employed in triple-negative and HER2-positive subtypes because it facilitates tumor downstaging, increases the likelihood of breast conservation, improves treatment compliance, and provides insight into tumor chemosensitivity through pathologic response assessment.[68][69]

Targeted therapy has transformed outcomes for biologically defined subgroups. Approximately 17% of breast cancers overexpress HER2/neu, and these patients benefit from HER2-directed therapy.[70] Trastuzumab, the first anti-HER2 monoclonal antibody, significantly reduces recurrence risk by about 52% and breast cancer mortality by 33% when added to chemotherapy in early HER2-positive disease compared with chemotherapy alone.[70][71] Dual HER2 blockade with trastuzumab and pertuzumab further improves response rates and pathologic complete response in high-risk patients. PARP inhibitors such as olaparib and talazoparib target DNA repair mechanisms in tumors with BRCA mutations; they are indicated in the adjuvant setting for individuals with germline BRCA mutations and HER2-negative breast cancer, providing an additional survival advantage in this genetically defined population.[72] CDK4/6 inhibitors (e.g., palbociclib) block cyclin-dependent kinases 4 and 6, key regulators of cell-cycle progression. When combined with endocrine therapy, they significantly enhance tumor control in HR-positive, HER2-negative metastatic disease and are being incorporated into selected high-risk early-stage HR-positive settings.[73] Immune checkpoint inhibitors such as pembrolizumab and nivolumab act on the PD-1/PD-L1 axis, restoring antitumor immune responses; they are currently used in triple-negative breast cancer, particularly in the metastatic and high-risk neoadjuvant/adjuvant context.[74]

Hormonal (endocrine) therapy is the backbone of treatment for HR-positive breast cancer across all stages. Selective estrogen receptor modulators like tamoxifen and aromatase inhibitors such as exemestane and letrozole are used to block estrogen signaling or reduce estrogen synthesis, thereby inhibiting tumor growth.[69] Tamoxifen is especially important in premenopausal women, whereas both SERMs and aromatase inhibitors can be used postmenopause.[31] Endocrine therapy reduces recurrence and mortality and is typically prescribed for 5 to 10 years, with extended therapy considered in higher-risk patients.[69][31] In premenopausal women, additional ovarian function suppression, via surgical oophorectomy or medical strategies such as GnRH analogs, can further lower estrogen exposure and improve outcomes, particularly in high-risk HR-positive disease.[75] Overall, medical oncology integrates these systemic options—chemotherapy, endocrine therapy, targeted agents, and immunotherapy—to tailor treatment according to tumor biology and patient factors, aiming to maximize survival benefits while minimizing toxicity and preserving quality of life.[64–75]

Staging

Breast cancer staging is a structured process that integrates both clinical and histopathologic data to categorize disease extent, estimate prognosis, and guide management decisions. Clinical staging is performed before treatment and is based on a thorough history, physical examination, and imaging, including mammography, ultrasound, MRI, and, when indicated, staging scans. Histopathologic staging is determined after definitive surgery, using microscopic evaluation of the primary tumor and regional lymph nodes. Together, these approaches provide a comprehensive picture of tumor burden and spread, allowing patients to be grouped into prognostic categories that correlate with outcomes and inform evidence-based treatment recommendations.[30] The TNM classification system, developed and periodically updated by the American Joint Committee on Cancer, is the most widely used framework for staging breast cancer.[30] The "T" component describes the size and extent of the primary tumor. Tis refers to carcinoma in situ, including ductal carcinoma in situ and Paget disease of the nipple without an underlying mass. T1 tumors measure less than 2 cm in greatest dimension and are further subclassified as T1a (0.1–0.5 cm), T1b (0.5–1.0 cm), and T1c (1.0–2.0 cm). T2 tumors range from 2 to 5 cm, while T3 tumors exceed 5 cm. T4 tumors are defined not only by size but by direct extension: T4a indicates chest wall involvement, T4b denotes skin involvement such as ulceration or satellite nodules, T4c combines chest wall and skin involvement, and T4d corresponds to inflammatory breast cancer, a particularly aggressive presentation.[30]

Nodal status, represented by "N," is a critical prognostic factor. N1 disease involves mobile ipsilateral axillary lymph nodes, while N2 indicates fixed or matted ipsilateral axillary nodes, suggesting more advanced regional disease. N3 encompasses spread to more distant regional nodal basins: N3a involves ipsilateral infraclavicular nodes, N3b refers to internal mammary node involvement, and N3c denotes ipsilateral supraclavicular node metastases, all of which imply a higher risk of systemic dissemination.[30] The "M" component captures the presence of distant metastasis; M1 disease signifies spread beyond regional nodes to organs such as bone, liver, lung, or brain.[30] These TNM elements are combined to assign an overall stage group. Stage 0 includes noninvasive disease such as ductal carcinoma in situ (DCIS). Early invasive cancers, typically stages I, IIa, and IIb, are generally confined to the breast and limited regional nodes. Locally advanced cancers, classified as stages IIIa, IIIb, and IIIc, usually feature larger primary tumors, extensive nodal involvement, or direct extension to the chest wall or skin. Stage IV designates metastatic disease, in which cancer has spread to distant organs.[68] This staging framework underpins prognostic estimates and forms the foundation for selecting appropriate local and systemic treatments, from breast-conserving surgery and adjuvant therapy in early stages to multimodal and palliative strategies in advanced disease.

Prognosis

The prognosis of breast cancer is closely linked to stage at diagnosis, reflecting the burden of disease and likelihood of systemic spread. In general, earlier stages are associated with excellent outcomes, while advanced and metastatic disease carries a much poorer outlook. For Stage 0 disease, which includes ductal carcinoma in situ (DCIS) and other noninvasive breast neoplasms, the 5-year survival rate approaches 100%, reflecting the absence of stromal invasion and the very low risk of distant metastasis.[30] Stage I invasive breast cancer, characterized by small primary tumors with minimal or no nodal involvement, also has an outstanding prognosis, with 5-year survival likewise near 100% when appropriately treated.[30] These figures underscore the life-saving potential of early detection and timely intervention. As disease burden increases, prognosis gradually worsens. Stage II breast cancer, which typically involves larger tumors and/or limited nodal involvement, still has a very favorable outlook, with approximately 93% of patients surviving at least 5 years.[30] This high survival rate reflects advances in surgery, radiation, and systemic therapy, including chemotherapy, endocrine therapy, and targeted agents, which have collectively improved local control and reduced the risk of distant recurrence. Stage III breast cancer, usually categorized as locally advanced due to larger tumors, significant regional nodal disease, or involvement of the chest wall or skin, has a more guarded prognosis. The 5-year survival rate for Stage III disease is about 72%, representing a substantial decline compared with earlier stages but still reflecting the potential for cure in a significant proportion of patients with aggressive multimodal treatment.[30]

Once breast cancer spreads beyond the regional lymph nodes to distant organs, it is classified as Stage IV, or metastatic breast cancer, and prognosis declines dramatically. Only about 22% of patients with Stage IV disease are expected to survive 5 years from diagnosis, despite considerable progress in systemic therapy.[30] Survival in this setting is highly variable and depends on tumor biology, sites of metastasis, response to treatment, and patient performance status. Hormone receptor–positive or HER2-positive metastatic cancers may be controlled for prolonged periods with modern systemic regimens, whereas triple-negative metastatic disease often follows a more aggressive course. Overall, these survival statistics highlight both the success of early-stage breast cancer management and the ongoing challenges posed by advanced and metastatic disease, reinforcing the importance of early detection, optimal staging, and individualized treatment planning.

Complications

Breast cancer management relies on multimodal therapy, and each component—surgery, chemotherapy, endocrine therapy, and radiation—

carries potential complications that can affect both short- and long-term quality of life. Surgical interventions, ranging from lumpectomy to mastectomy with or without reconstruction, are associated with risks such as infection, bleeding, seroma formation, and postoperative pain. Permanent scarring and cosmetic asymmetry may occur, particularly when large volumes of tissue are removed or when reconstruction is complex. Alterations in sensation, including numbness or hypersensitivity in the chest wall, nipple-areolar complex, or reconstructed breast, are common and may persist long term. In axillary surgery, patients face an additional risk of shoulder stiffness and lymphedema, especially after full axillary lymph node dissection.[30] Cytotoxic chemotherapy can lead to a wide spectrum of systemic side effects. Acute toxicities include nausea, vomiting, diarrhea, mucositis, and profound fatigue. Alopecia is a frequent and distressing complication, often requiring psychosocial support. Neurotoxicity, particularly with taxanes and platinum agents, may manifest as peripheral neuropathy with numbness, tingling, or pain in the hands and feet, which can be dose-limiting and sometimes irreversible. Many patients report cognitive changes described as "chemo brain," including difficulties with memory, concentration, and executive functioning. Chemotherapy may also induce premature menopause, with associated symptoms such as hot flashes, night sweats, vaginal dryness, and decreased fertility, which are particularly significant for younger women. In males with breast cancer, chemotherapy and associated endocrine treatments can cause sexual dysfunction.[64][65]

Hormonal therapy, including selective estrogen receptor modulators like tamoxifen and aromatase inhibitors, introduces its own complication profile. Common side effects include hot flashes, vaginal dryness or discharge, mood changes, and fatigue. Aromatase inhibitors may also increase the risk of arthralgias, myalgias, and bone loss, predisposing to osteoporosis and fractures. In men treated with endocrine therapy, impotence and decreased libido can significantly impact quality of life. Radiation therapy contributes additional acute and late toxicities. Early effects often include skin erythema, desquamation, pain, and fatigue. Over time, patients may develop breast fibrosis, shrinkage, and changes in texture, which can alter cosmesis and cause discomfort. More serious late complications include chronic heart and lung injury, particularly in left-sided irradiation, with risks of ischemic heart disease and radiation pneumonitis. Neuropathy, such as brachial plexopathy, may occur rarely when regional nodal basins receive high doses.[76][30] Recognizing these potential complications and managing them proactively through supportive care, rehabilitation, and careful treatment planning is essential to preserving quality of life while maximizing oncologic outcomes.

Patient Education

Deterrence and patient education are fundamental components of breast cancer control, complementing therapeutic advances by focusing on prevention, early detection, and long-term survivorship. Because breast cancer is the most commonly diagnosed cancer in women, addressing modifiable risk factors—such as obesity, alcohol consumption, physical inactivity, and hormone exposure—is vital to reducing overall incidence. Public health campaigns and clinical counseling that promote healthy lifestyle choices, breastfeeding, and awareness of family history can empower women to engage in risk-reducing behaviors and seek timely medical evaluation when concerns arise. For individuals with strong family histories or known genetic predispositions, genetic counseling and testing for mutations such as BRCA1 and BRCA2 can identify those who may benefit from intensified surveillance, chemoprevention, or prophylactic surgery. Screening is a cornerstone of deterrence by facilitating the detection of premalignant lesions and early-stage cancers before they become clinically evident. Mammography remains the primary screening tool, with ultrasound and MRI used as adjuncts in women with dense breasts or high-risk features. Educating patients about the purpose, benefits, and limitations of screening helps improve adherence to recommended schedules and reduces anxiety associated with abnormal findings. When a suspicious lesion is detected, prompt biopsy and histopathologic evaluation, including assessment of molecular markers, ensure accurate diagnosis and appropriate classification of disease. Early breast cancer is typically managed with breast-conserving surgery, radiation, chemotherapy, and/or hormonal therapy, and comprehensive patient education about these modalities allows shared decision-making and improves treatment acceptance and adherence.

As treatment becomes more complex, it is crucial to counsel patients on the importance of completing prescribed therapy and attending follow-up visits. Long-term surveillance after primary treatment is essential for detecting local recurrence, contralateral breast cancer, or metastatic disease at an early, more treatable stage. Follow-up regimens may include periodic history and physical examination, annual mammography, and tailored imaging or laboratory tests based on symptoms and risk factors. Education should also address potential late effects of therapy, such as lymphedema, cardiotoxicity, bone loss, and psychosocial issues including anxiety, depression, and body image concerns. Survivorship care plans, which outline recommended monitoring, lifestyle guidance, and symptom management strategies, can help patients transition from active treatment to long-term follow-up. Overall, effective

deterrence and patient education require clear communication, cultural sensitivity, and individualized counseling. By ensuring that patients understand their risks, the rationale for screening, and the goals of treatment and surveillance, clinicians can enhance early detection, promote adherence, and ultimately contribute to improved outcomes and quality of life for women at risk for or living with breast cancer.

Enhancing Healthcare Team Outcomes

Optimal care for patients with breast cancer depends on a coordinated, patient-centered, interprofessional approach. From the time a suspicious lesion is identified—often during routine screening—multiple healthcare professionals become involved in diagnosis, staging, treatment, and survivorship. Radiologists play a key role in detecting abnormalities on mammography, ultrasound, or MRI and in performing image-guided biopsies. Their ability to accurately interpret imaging, classify lesions, and communicate results clearly to both patients and the treating team is crucial for timely and appropriate workup. Pathologists then evaluate biopsy and surgical specimens, providing definitive histologic diagnosis, grading, and molecular profiling, including hormone receptors and HER2 status, upon which systemic therapy decisions are based. Medical oncologists, surgical oncologists, radiation oncologists, and plastic surgeons collaborate to design individualized treatment plans that integrate surgery, systemic therapy, and radiation in a sequence that maximizes tumor control while minimizing toxicity. For example, decisions about neoadjuvant versus adjuvant chemotherapy, the extent of surgery, and the need for post-mastectomy radiation are best made in multidisciplinary tumor boards where diverse perspectives can be considered. Advanced practice clinicians, including nurse practitioners and physician assistants, contribute by managing day-to-day clinical issues, monitoring symptoms, and providing education and psychosocial support. Pharmacists ensure safe and effective use of chemotherapeutic agents, endocrine therapies, targeted drugs, and supportive medications, monitoring for interactions and adverse effects.

Nurses are central to patient education, symptom management, and care coordination. They help patients navigate complex treatment pathways, recognize early signs of complications such as infection, lymphedema, or cardiotoxicity, and adhere to oral and infusional therapies. Primary care physicians remain important throughout the cancer journey, managing comorbidities, reinforcing screening and lifestyle advice, and collaborating on survivorship care once active oncologic treatment is completed. Social workers, psychologists, nutritionists, and rehabilitation specialists further enhance outcomes by addressing emotional, nutritional, functional, and financial challenges that may undermine adherence or quality of life. A well-functioning healthcare team also focuses on ensuring continuity of surveillance. Systems that track follow-up appointments, imaging, and laboratory tests help prevent patients from being lost to follow-up, which is critical for early identification of recurrence or late treatment effects. Regular multidisciplinary meetings have shared electronic health records, and clear communication pathways all contribute to effective team-based care. Ultimately, by working collaboratively and placing the patient at the center of decision-making, the healthcare team can improve clinical outcomes, support psychosocial well-being, and deliver high-quality, comprehensive care across the continuum of breast cancer management.

Conclusion:

In conclusion, the management of breast cancer has evolved into a highly sophisticated, multidisciplinary endeavor that successfully integrates surgery, radiation oncology, and medical oncology to deliver personalized care. The cornerstone of this approach is the recognition that breast cancer is not a single disease but a collection of distinct molecular subtypes, each with unique prognostic implications and therapeutic vulnerabilities. Treatment strategies are therefore meticulously tailored, moving beyond simple anatomical staging to incorporate critical biomarkers like hormone receptors and HER2 status. This paradigm allows for the selective use of targeted therapies and immunotherapy, which have dramatically improved outcomes, particularly for aggressive subtypes like HER2-positive and triple-negative breast cancer. The success of modern breast cancer care is fundamentally dependent on the seamless collaboration of a dedicated interprofessional team. From radiologists and pathologists who ensure accurate diagnosis and subtyping, to surgeons, medical and radiation oncologists who devise and execute complex treatment plans, and supported by nurses, pharmacists, and rehabilitation specialists, each member plays a vital role. This collaborative model ensures that care is not only effective in controlling the disease but also holistic, addressing the patient's physical, emotional, and quality-of-life needs throughout their journey. Ultimately, the continued advancement and implementation of this integrated, evidence-based approach are essential for further improving survival rates and the overall well-being of patients with breast cancer globally.

References:

1. Watkins EJ. Overview of breast cancer. JAAPA : official journal of the American Academy of Physician Assistants. 2019 Oct:32(10):13-17. doi: 10.1097/01.JAA.0000580524.95733.3d.
2. Alex A, Bhandary E, McGuire KP. Anatomy and Physiology of the Breast during Pregnancy and Lactation. Advances in experimental medicine and biology.

2020:1252():3-7. doi: 10.1007/978-3-030-41596-9_1.
3. Kashyap D, Pal D, Sharma R, Garg VK, Goel N, Koundal D, Zaguia A, Koundal S, Belay A. Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures. BioMed research international. 2022:2022():9605439. doi: 10.1155/2022/9605439.
4. PDQ Screening and Prevention Editorial Board. Breast Cancer Screening (PDQ®): Health Professional Version. PDQ Cancer Information Summaries. 2002
5. Doren A, Vecchiola A, Aguirre B, Villaseca P. Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations. Climacteric : the journal of the International Menopause Society. 2018 Dec:21(6):529-535. doi: 10.1080/13697137.2018.1514006.
6. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians. 2021 May:71(3):209-249. doi: 10.3322/caac.21660.
7. Parada H Jr, Sun X, Tse CK, Olshan AF, Troester MA. Lifestyle Patterns and Survival Following Breast Cancer in the Carolina Breast Cancer Study. Epidemiology (Cambridge, Mass.). 2019 Jan:30(1):83-92. doi: 10.1097/EDE.0000000000000933.
8. White AJ, Bradshaw PT, Hamra GB. Air pollution and Breast Cancer: A Review. Current epidemiology reports. 2018 Jun:5(2):92-100. doi: 10.1007/s40471-018-0143-2.
9. Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, Elias AD, Baskin-Bey ES, Cardoso F. Male breast cancer: a disease distinct from female breast cancer. Breast cancer research and treatment. 2019 Jan:173(1):37-48. doi: 10.1007/s10549-018-4921-9.
10. Azamjah N, Soltan-Zadeh Y, Zayeri F. Global Trend of Breast Cancer Mortality Rate: A 25-Year Study. Asian Pacific journal of cancer prevention : APJCP. 2019 Jul 1:20(7):2015-2020. doi: 10.31557/APJCP.2019.20.7.2015.
11. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet (London, England). 2001 Oct 27:358(9291):1389-99
12. Roulot A, Héquet D, Guinebretière JM, Vincent-Salomon A, Lerebours F, Dubot C, Rouzier R. Tumoral heterogeneity of breast cancer. Annales de biologie clinique. 2016 Dec 1:74(6):653-660
13. Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, Díez M, Viladot M, Arance A, Muñoz M. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast (Edinburgh, Scotland). 2015 Nov:24 Suppl 2():S26-35. doi: 10.1016/j.breast.2015.07.008.
14. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature. 2000 Aug 17:406(6797):747-52
15. McCart Reed AE, Kalinowski L, Simpson PT, Lakhani SR. Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. Breast cancer research : BCR. 2021 Jan 7:23(1):6. doi: 10.1186/s13058-020-01384-6.
16. Roux P, Knight S, Cohen M, Classe JM, Mazouni C, Chauvet MP, Reyal F, Colombo PE, Jouve E, Chopin N, Daraï E, Coutant C, Lambaudie E, Houvenaeghel G. Tubular and mucinous breast cancer: results of a cohort of 917 patients. Tumori. 2019 Feb:105(1):55-62. doi: 10.1177/0300891618811282.
17. Cserni G. Histological type and typing of breast carcinomas and the WHO classification changes over time. Pathologica. 2020 Mar:112(1):25-41. doi: 10.32074/1591-951X-1-20.
18. . Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women. Obstetrics and gynecology. 2017 Jul:130(1):e1-e16. doi: 10.1097/AOG.0000000000002158.
19. Baines CJ. Physical examination of the breasts in screening for breast cancer. Journal of gerontology. 1992 Nov:47 Spec No():63-7
20. Menta A, Fouad TM, Lucci A, Le-Petross H, Stauder MC, Woodward WA, Ueno NT, Lim B. Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer. The Surgical clinics of North America. 2018 Aug:98(4):787-800. doi: 10.1016/j.suc.2018.03.009.
21. Henderson JA, Duffee D, Ferguson T. Breast Examination Techniques. StatPearls. 2025 Jan:():

22. Jackson VP. Diagnostic mammography. Radiologic clinics of North America. 2004 Sep:42(5):853-70,
23. Mann RM, Kuhl CK, Moy L. Contrast-enhanced MRI for breast cancer screening. Journal of magnetic resonance imaging : JMRI. 2019 Aug:50(2):377-390. doi: 10.1002/jmri.26654. Epub 2019 Jan 18
24. Nielsen S, Narayan AK. Breast Cancer Screening Modalities, Recommendations, and Novel Imaging Techniques. The Surgical clinics of North America. 2023 Feb:103(1):63-82. doi: 10.1016/j.suc.2022.08.004.
25. Magny SJ, Shikhman R, Keppke AL. Breast Imaging Reporting and Data System. StatPearls. 2024 Jan
26. Radovic N, Ivanac G, Divjak E, Biondic I, Bulum A, Brkljacic B. Evaluation of Breast Cancer Morphology Using Diffusion-Weighted and Dynamic Contrast-Enhanced MRI: Intermethod and Interobserver Agreement. Journal of magnetic resonance imaging : JMRI. 2019 May:49(5):1381-1390. doi: 10.1002/jmri.26332.
27. Pediconi F, Marzocca F, Cavallo Marincola B, Napoli A. MRI-guided treatment in the breast. Journal of magnetic resonance imaging : JMRI. 2018 Dec:48(6):1479-1488. doi: 10.1002/jmri.26282.
28. Watanabe Y, Anan K. The decision to perform or omit sentinel lymph node biopsy during mastectomy for ductal carcinoma in situ should be tailored in accordance with preoperative findings. Breast cancer (Tokyo, Japan). 2019 Mar:26(2):261-262. doi: 10.1007/s12282-018-0917-x.
29. Verma P, Sharma R, Sharma N, Gulati A, Parashar A, Kaundal A. Fine-Needle Aspiration Cytology versus Core-Needle Biopsy for Breast Lesions: A Dilemma of Superiority between the Two. Acta cytologica. 2021:65(5):411-416. doi: 10.1159/000517005.
30. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns J, Kumar R. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2022 Jun:20(6):691-722. doi: 10.6004/jnccn.2022.0030.
31. Kerr AJ, Dodwell D, McGale P, Holt F, Duane F, Mannu G, Darby SC, Taylor CW. Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality. Cancer treatment reviews. 2022 Apr:105():102375. doi: 10.1016/j.ctrv.2022.102375.
32. Shien T, Iwata H. Adjuvant and neoadjuvant therapy for breast cancer. Japanese journal of clinical oncology. 2020 Mar 9:50(3):225-229. doi: 10.1093/jjco/hyz213.
33. Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019 Jan 22:321(3):288-300. doi: 10.1001/jama.2018.19323.
34. Czajka ML, Pfeifer C. Breast Cancer Surgery. StatPearls. 2024 Jan
35. Goethals A, Rose J. Mastectomy. StatPearls. 2024 Jan
36. Sevensma KE, Lewis CR. Axillary Sentinel Lymph Node Biopsy. StatPearls. 2023 Jan:():
37. Toomey AE, Lewis CR. Axillary Lymphadenectomy. StatPearls. 2024 Jan
38. Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, Land SR, Margolese RG, Swain SM, Costantino JP, Wolmark N. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. Journal of the National Cancer Institute. 2011 Mar 16:103(6):478-88. doi: 10.1093/jnci/djr027.
39. Litière S, Werutsky G, Fentiman IS, Rutgers E, Christiaens MR, Van Limbergen E, Baaijens MH, Bogaerts J, Bartelink H. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. The Lancet. Oncology. 2012 Apr:13(4):412-9. doi: 10.1016/S1470-2045(12)70042-6.
40. Wang X, Xu L, Yin Z, Wang D, Wang Q, Xu K, Zhao J, Zhao L, Yuan Z, Wang P. Locoregional recurrence-associated factors and risk-adapted postmastectomy radiotherapy for breast cancer staged in cT1-2N0-1 after neoadjuvant chemotherapy. Cancer management and research. 2018:10():4105-4112. doi: 10.2147/CMAR.S173628.
41. Tang L, Matsushita H, Jingu K. Controversial issues in radiotherapy after breast-conserving surgery for early breast cancer in older patients: a systematic review. Journal of radiation research. 2018 Nov 1:59(6):789-793. doi: 10.1093/jrr/rry071.
42. Kirby AM. Updated ASTRO guidelines on accelerated partial breast irradiation (APBI): to whom can we offer APBI outside a clinical trial? The British journal of radiology. 2018

May:91(1085):20170565. doi: 10.1259/bjr.20170565.

43. Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA, Kuske RR, Ganz PA, Parda DS, Scheier MF, Winter KA, Paik S, Kuerer HM, Vallow LA, Pierce LJ, Mamounas EP, McCormick B, Costantino JP, Bear HD, Germain I, Gustafson G, Grossheim L, Petersen IA, Hudes RS, Curran WJ Jr, Bryant JL, Wolmark N. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet (London, England). 2019 Dec 14:394(10215):2155-2164. doi: 10.1016/S0140-6736(19)32514-0.
44. Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad WJ, Oei SB, Wárlám-Rodenhuis CC, Pierart M, Collette L. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Aug 1:25(22):3259-65
45. Overgaard M, Nielsen HM, Tramm T, Højris I, Grantzau TL, Alsner J, Offersen BV, Overgaard J, DBCG Radiotherapy Group. Postmastectomy radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. A 30-year long-term report from the Danish breast cancer cooperative group DBCG 82bc trial. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2022 May:170():4-13. doi: 10.1016/j.radonc.2022.03.008.
46. Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JH, Orzalesi L, Bouma WH, van der Mijle HC, Nieuwenhuijzen GA, Veltkamp SC, Slaets L, Duez NJ, de Graaf PW, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JW, Belkacemi Y, Petignat P, Schinagl DA, Coens C, Messina CG, Bogaerts J, Rutgers EJ. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. The Lancet. Oncology. 2014 Nov:15(12):1303-10. doi: 10.1016/S1470-2045(14)70460-7.
47. Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, Vallis KA, White JR, Rousseau P, Fortin A, Pierce LJ, Manchul L, Chafe S, Nolan MC, Craighead P, Bowen J, McCready DR, Pritchard KI, Gelmon K, Murray Y, Chapman JA, Chen BE, Levine MN, MA.20 Study Investigators. Regional Nodal Irradiation in Early-Stage Breast Cancer. The New England journal of medicine. 2015 Jul 23:373(4):307-16. doi: 10.1056/NEJMoa1415340.
48. Choi KH, Ahn SJ, Jeong JU, Yu M, Kim JH, Jeong BK, Lee JH, Kim SH, Lee JH. Postoperative radiotherapy with intensity-modulated radiation therapy versus 3-dimensional conformal radiotherapy in early breast cancer: A randomized clinical trial of KROG 15-03. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2021 Jan:154():179-186. doi: 10.1016/j.radonc.2020.09.043.
49. Pignol JP, Truong P, Rakovitch E, Sattler MG, Whelan TJ, Olivotto IA. Ten years results of the Canadian breast intensity modulated radiation therapy (IMRT) randomized controlled trial. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2016 Dec:121(3):414-419. doi: 10.1016/j.radonc.2016.08.021.
50. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. The New England journal of medicine. 2013 Mar 14:368(11):987-98. doi: 10.1056/NEJMoa1209825.
51. Epler GR, Kelly EM. Systematic review of postradiotherapy bronchiolitis obliterans organizing pneumonia in women with breast cancer. The oncologist. 2014 Dec:19(12):1216-26. doi: 10.1634/theoncologist.2014-0041.
52. Taghian AG, Assaad SI, Niemierko A, Floyd SR, Powell SN. Is a reduction in radiation lung volume and dose necessary with paclitaxel chemotherapy for node-positive breast cancer? International journal of radiation oncology, biology, physics. 2005 Jun 1:62(2):386-91
53. Williams NR, Williams S, Kanapathy M, Naderi N, Vavourakis V, Mosahebi A. Radiation-induced fibrosis in breast cancer: A protocol for an observational cross-sectional pilot study for personalised risk estimation and objective assessment. International journal of surgery protocols. 2019:14():9-13. doi: 10.1016/j.isjp.2019.02.002.

54. Collette S, Collette L, Budiharto T, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad W, Mueller RP, Kurtz J, Morgan DA, Dubois JB, Salamon E, Mirimanoff R, Bolla M, Van der Hulst M, Wárlám-Rodenhuis CC, Bartelink H, EORTC Radiation Oncology Group. Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'. European journal of cancer (Oxford, England : 1990). 2008 Nov:44(17):2587-99. doi: 10.1016/j.ejca.2008.07.032.
55. Jacobson G, Bhatia S, Smith BJ, Button AM, Bodeker K, Buatti J. Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter. International journal of radiation oncology, biology, physics. 2013 Mar 1:85(3):604-8. doi: 10.1016/j.ijrobp.2012.06.042.
56. Gross JP, Whelan TJ, Parulekar WR, Chen BE, Rademaker AW, Helenowski IB, Donnelly ED, Strauss JB. Development and Validation of a Nomogram to Predict Lymphedema After Axillary Surgery and Radiation Therapy in Women With Breast Cancer From the NCIC CTG MA.20 Randomized Trial. International journal of radiation oncology, biology, physics. 2019 Sep 1:105(1):165-173. doi: 10.1016/j.ijrobp.2019.05.002.
57. DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. The Lancet. Oncology. 2013 May:14(6):500-15. doi: 10.1016/S1470-2045(13)70076-7.
58. Bartels SAL, Donker M, Poncet C, Sauvé N, Straver ME, van de Velde CJH, Mansel RE, Blanken C, Orzalesi L, Klinkenbijl JHG, van der Mijle HCJ, Nieuwenhuijzen GAP, Veltkamp SC, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JWS, Belkacemi Y, Petignat P, Schinagl DAX, Coens C, van Tienhoven G, van Duijnhoven F, Rutgers EJT. Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Apr 20:41(12):2159-2165. doi: 10.1200/JCO.22.01565.
59. Pierce SM, Recht A, Lingos TI, Abner A, Vicini F, Silver B, Herzog A, Harris JR. Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. International journal of radiation oncology, biology, physics. 1992:23(5):915-23
60. Meric F, Buchholz TA, Mirza NQ, Vlastos G, Ames FC, Ross MI, Pollock RE, Singletary SE, Feig BW, Kuerer HM, Newman LA, Perkins GH, Strom EA, McNeese MD, Hortobagyi GN, Hunt KK. Long-term complications associated with breast-conservation surgery and radiotherapy. Annals of surgical oncology.
61. Grantzau T, Overgaard J. Risk of second non-breast cancer after radiotherapy for breast cancer: a systematic review and meta-analysis of 762,468 patients. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2015 Jan:114(1):56-65. doi: 10.1016/j.radonc.2014.10.004.
62. Ye JC, Yan W, Christos P, Nori D, Chao KS, Ravi A. Second cancer, breast cancer, and cardiac mortality in stage T1aN0 breast cancer patients with or without external beam radiation therapy: a national registry study. Clinical breast cancer. 2015 Feb:15(1):54-9. doi: 10.1016/j.clbc.2014.07.003.
63. Dracham CB, Shankar A, Madan R. Radiation induced secondary malignancies: a review article. Radiation oncology journal. 2018 Jun:36(2):85-94. doi: 10.3857/roj.2018.00290.
64. Burguin A, Diorio C, Durocher F. Breast Cancer Treatments: Updates and New Challenges. Journal of personalized medicine. 2021 Aug 19:11(8):. doi: 10.3390/jpm11080808.
65. Amjad MT, Chidharla A, Kasi A. Cancer Chemotherapy. StatPearls. 2025 Jan:
66. Syed YY. Oncotype DX Breast Recurrence Score(®): A Review of its Use in Early-Stage Breast Cancer. Molecular diagnosis & therapy. 2020 Oct:24(5):621-632. doi: 10.1007/s40291-020-00482-7.
67. Andre F, Ismaila N, Allison KH, Barlow WE, Collyar DE, Damodaran S, Henry NL, Jhaveri K, Kalinsky K, Kuderer NM, Litvak A, Mayer EL, Pusztai L, Raab R, Wolff AC, Stearns V. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Jun 1:40(16):1816-1837. doi: 10.1200/JCO.22.00069.
68. Trayes KP, Cokenakes SEH. Breast Cancer Treatment. American family physician. 2021 Aug 1:104(2):171-178

69. Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, Khan SA, Loibl S, Morris EA, Perez A, Regan MM, Spears PA, Sudheendra PK, Symmans WF, Yung RL, Harvey BE, Hershman DL. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 May 1:39(13):1485-1505. doi: 10.1200/JCO.20.03399.
70. Wu YT, Xu Z, Zhang K, Wu JS, Li X, Arshad B, Li YC, Wang ZL, Li HY, Wu KN, Kong LQ. Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis. Therapeutics and clinical risk management. 2018:14():1789-1797. doi: 10.2147/TCRM.S176214.
71. Dieci MV, Vernaci G, Guarneri V. Escalation and de-escalation in HER2 positive early breast cancer. Current opinion in oncology. 2019 Jan:31(1):35-42. doi: 10.1097/CCO.0000000000000492.
72. Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, Vishakha, Behl T, Jha SK, Tang H. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Molecular cancer. 2023 Jul 6:22(1):105. doi: 10.1186/s12943-023-01805-y.
73. Husinka L, Koerner PH, Miller RT, Trombatt W. Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer. Journal of drug assessment. 2020 Dec 18:10(1):27-34. doi: 10.1080/21556660.2020.1857103.
74. Debien V, De Caluwé A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, Buisseret L. Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ breast cancer. 2023 Feb 13:9(1):7. doi: 10.1038/s41523-023-00508-3.
75. Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet (London, England). 2021 May 8:397(10286):1750-1769. doi: 10.1016/S0140-6736(20)32381-3.
76. Al-Hilli Z, Wilkerson A. Breast Surgery: Management of Postoperative Complications Following Operations for Breast Cancer. The Surgical clinics of North America. 2021 Oct:101(5):845-863. doi: 10.1016/j.suc.2021.06.014.
77. Pike M, Training unit clerks. Hospitals. 1970 May 16